靶向肠道菌群代谢产物防治非酒精性脂肪性肝病*

doi:10.3969/j.issn.1672-5069.2017.06.001

Abstract

Yang Ruixu, Zhou Da, Fan Jiangao. Microbiome-based metabolite in the treatment of patients with non-alcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 643-646.

[1] 金沛桦,施军平. NAFLD: 一种多系统疾病. 实用肝脏病杂志, 2017,20（3）:257-259.
[2] Tremaroli V,Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature,2012,489（7415）:242-249.
[3] Gkolfakis P,Dimitriadis G,Triantafyllou K. Gut microbiota and non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int,2015,14（6）:572-581.
[4] Compare D,Coccoli P,Rocco A,et al. Gut-liver axis:the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis,2012,22（6）:471-476.
[5] Suez J,Elinav E. The path towards microbiome-based metabolite treatment. Nat Microbiol,2017,2:17075.
[6] Nieuwdorp M,Gilijamse PW,Pai N,Kaplan LM. Role of the microbiome in energy regulation and metabolism. Gastroenterology,2014,146（6）:1525-1533.
[7] Le Chatelier E,Nielsen T,Qin J,et al. Richness of human gut microbiome correlates with metabolic markers. Nature,2013,500（7464）:541-546.
[8] Mouzaki M,Comelli EM,Arendt BM,et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology,2013,58（1）:120-127.
[9] 沈峰,陈建能,郑瑞丹,等. 应用454测序技术评价NAFLD患者肠道菌群结构差异. 实用肝脏病杂志,2015,18（2）:145-149.
[10] Zhu L,Baker SS,Gill C,et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis（NASH） patients:a connection between endogenous alcohol and NASH. Hepatology,2013,57（2）:601-609.
[11] Boursier J,Mueller O,Barret M,et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatolo gy,2016,63（3）:764-775.
[12] Wong VW,Tse CH,Lam TT,et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis-a longitudinal study. PLoS One,2013,8（4）:e62885.
[13] 曹毅,沈峰,徐雷鸣,范建高. 肠道菌群和内毒素血症与NAFLD. 实用肝脏病杂志,2012,15（2）:163-165.
[14] Fuller R. Probiotics in man and animals. J Appl Bacteriol,1989,66（5）:365-378.
[15] Zhu A,Sunagawa S,Mende DR,et al. Inter-individual differences in the gene content of human gut bacterial species. Genome Biol,2015,16:82.
[16] Nayfach S,Rodriguez-Mueller B,Garud N,et al. An integrated metagenomics pipeline for strain profiling reveals novel patterns of bacterial transmission and biogeography. Genome Res,2016,26（11）:1612-1625.
[17] Maldonado-Gomez MX,Martinez I,Bottacini F,et al. Stable engraftment of bifidobacterium longum AH1206 in the human gut depends on individualized features of the resident microbiome. Cell Host Microbe,2016,20（4）:515-526.
[18] Zeevi D,Korem T,Zmora N,et al. Personalized nutrition by prediction of glycemic responses. Cell,2015,163（5）:1079-1094.
[19] Gao X,Zhu Y,Wen Y,et al. Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children:A meta-analysis of randomized controlled trials. Hepatol Res,2016,46（12）:1226-1233.
[20] Smits LP,Bouter KE,De Vos WM,et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology,2013,145（5）:946-953.
[21] Vrieze A,Van Nood E,Holleman F,et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology,2012,143（4）:913-916 e917.
[22] Paramsothy S,Kamm MA,Kaakoush NO,et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis:a randomised placebo-controlled trial. Lancet,2017,389（10075）:1218-1228.
[23] Bakker GJ,Nieuwdorp M. Fecal microbiota transplantation: Therapeutic potential for a multitude of diseases beyond clostridium difficile. Microbiol Spectr,2017,5（4）:ePub.
[24] Zhou D,Pan Q,Shen F,et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep,2017,7（1）:1529.
[25] Moayyedi P,Surette MG,Kim PT,et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology,2015,149（1）:102-109 e106.
[26] Bindels LB,Delzenne NM,Cani PD,et al. Towards a more comprehensive concept for prebiotics. Nat Rev Gastroenterol Hepatol,2015,12（5）:303-310.
[27] Beserra BT,Fernandes R,Do Rosario VA,et al. A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia,insulin concentrations and lipid parameters in adult patients with overweight or obesity. Clin Nutr,2015,34（5）:845-858.
[28] Ford AC,Quigley EM,Lacy BE,et al. Efficacy of prebiotics, probiotics,and synbiotics in irritable bowel syndrome and chronic idiopathic constipation:systematic review and meta-analysis. Am J Gastroenterol,2014,109（10）:1547-1561;quiz 1546, 1562.
[29] 徐正婕,范建高,王国良,等. 乳果糖对大鼠非酒精性脂肪性肝炎模型形成的影响. 中华消化杂志,2003,23（2）:97-100.
[30] Walker AW,Ince J,Duncan SH,et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J,2011,5（2）:220-230.
[31] Mcintyre A,Gibson PR,Young GP. Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut,1993,34（3）:386-391.
[32] Hinnebusch BF,Meng S,Wu JT,et al. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr,2002,132（5）:1012-1017.
[33] De Vadder F,Kovatcheva-Datchary P,Goncalves D,et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell,2014,156（1-2）:84-96.
[34] Gao Z,Yin J,Zhang J,et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes,2009,58（7）:1509-1517.
[35] Lin HV,Frassetto A,Kowalik EJ,Jr.,et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One,2012,7（4）:e35240.
[36] Donohoe DR,Garge N,Zhang X,et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab,2011,13（5）:517-526.
[37] Atarashi K,Tanoue T,Shima T,et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science,2011,331（6015）:337-341.
[38] Smith PM,Howitt MR,Panikov N,et al. The microbial metabolites,short-chain fatty acids,regulate colonic Treg cell homeostasis. Science,2013,341（6145）:569-573.
[39] Round JL,Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA,2010,107（27）:12204-12209.
[40] 周达,范建高. 肠道菌群-SCFAs在代谢性疾病中的作用研究. 胃肠病学和肝病学杂志,2016,25（3）:330-332.
[41] Clarke G,Stilling RM,Kennedy PJ,et al. Minireview:Gut microbiota:the neglected endocrine organ. Mol Endocrinol,2014,28（8）:1221-1238.

Microbiome-based metabolite in the treatment of patients with non-alcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[2]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[3]	Fu Liang, Wu Dongbing, Ji Xinzun. Application of ARFI quantification in the evaluation of liver injuries in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 377-380.
[4]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[5]	Su Shuting, Zhong Yan, Mi Yuqiang.. Management of patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 293-296.
[6]	Zhang Feng, Yan Yan.. Implication of serum apolipoprotein B levels and its correlation with metabolic syndrome in checked-up individuals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 61-64.
[7]	Song Na, Liu Xiaoyan, Liu Chang, et al.. Changes of plasma thyrotropin levels in patients with nonalcoholic fatty liver disease and type 2 diabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 65-68.
[8]	Cui Qinghua, Tao Hong, Wang Xiaoyue, et al.. Changes of serum glycosylated hemoglobin level and cardiac functions in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 69-72.
[9]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[10]	Dong Xuelian, Zhang Wenjun.. Application of controlled attenuation parameter in screening individuals with risk of metabolic syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 868-871.
[11]	Liu Yanghe, Long Dengyi, Bei Zheng, et al. Efficacy of bacillus subtilis duplex and polyene phosphatidylcholine combination in treatments of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 573-576.
[12]	Xie Zhanfeng, Jia Jizhen, Zhao Shufang. Combination of notoginseng total saponin and silybin in treatment of patients with non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 623-624.
[13]	Yang Yan, Wang Xuan. Diagnosis and treatment of patients with diabetic hepatopathy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 653-656.
[14]	Zhao Wentao, Cao Gaofeng, Jiao Xiaohong, et al. Efficacy of puerarin combined with metformin in the treatment of patients with non-alcoholic fatty liver disease and prediabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 409-412.
[15]	Yang Huimin, Jiang Chunyan. Clinical efficacy of herbal medicine and silibinin in the treatment of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 467-468.